

Background

Despite major advances in treatment and prevention, the HIV pandemic continues to pose a major global public health challenge. HPTN 083 is a phase 2b/3 randomized, double-blind, double-dummy trial that showed that long-acting injectable cabotegravir (CAB-LA) was superior to oral tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) in preventing HIV in cisgender men (MSM) and transgender women (TGW) who have sex with men. Pre-specified subpopulations historically underrepresented in PrEP registrational trials, including TGW, were successfully enrolled and retained in the study, thereby fostering inclusion and equity in scientific development. As transgender women (TGW) remain a priority group for HIV prevention, we report participant characteristics, safety, prevention efficacy, and pharmacokinetics (PK) of CAB-LA in TGW during the blinded phase of HPTN 083.

Methods

Participant characteristics, including gender affirming hormone therapy (GAHT) use, history of interpersonal violence, and HIV risk perception, were collected at baseline and throughout the study, and compared between TGW and cisgender MSM. Demographics were collected at screening by a healthcare professional.

The frequency of Grade 2+ adverse events (AEs) and incidence of curable STIs and HIV during the blinded phase of the trial were compared between TGW randomized to the TDF/FTC or CAB-LA.

In a subset of TGW who received all injections through study week 59 on time, CAB pharmacokinetics (PK) were compared between TGW in the presence or absence of GAHT.

Results

Of 4,566 participants enrolled in HPTN 083, 570 (12.5%) were TGW by self-identification. Age and geographic distributions are presented in **Table 1**. Among TGW, 330 (57.9%) reported GAHT use, with 249 at baseline and 81 initiating GAHT after enrollment. Among TGW enrolled in this trial, estradiol valerate was the most common medication accessed for gender affirmation.

TABLE 1. Participant Demographics, HPTN 083.

	Overall (n=4566)		TGW (n=570)		MSM (n=3996)	
	n	%	n	%	n	%
Age (years)						
18-29	3080	67.5%	471	82.6%	2609	65.3%
30-39	1048	23.0%	71	12.5%	977	24.4%
>40	438	9.6%	28	4.9%	410	10.3%
Geographic Region						
United States	1698	37.2%	125	21.9%	1573	39.4%
Latin America	1964	43.0%	205	36.0%	1759	44.0%
Asia	752	16.5%	225	39.5%	527	13.2%
Africa	152	3.3%	15	2.6%	137	3.4%

TABLE 2. Most common gender affirming medications reported among TGW during the blinded phase of HPTN 083.

Self-Reported GAHT Medication	Overall (n=330)		Reported GAHT Use at Baseline (n=249)		Reported GAHT Initiation Post-Enrollment (n=81)	
	n	%	n	%	n	%
Cyproterone acetate; Ethinylestradiol	88	26.7%	74	29.7%	14	17.3%
Estradiol valerate	147	44.5%	110	44.2%	37	45.7%
Estradiol	94	28.5%	79	31.7%	15	18.5%
Spirolactone	107	32.4%	79	31.7%	28	34.6%

References

Landovitz RJ, Donnell D, Clement ME, Hanscom B, Cottle L, Coelho L, Cabello R, Chariyalertsak S, Dunne EF, Frank I, Gallardo-Cartagena JA, Gaur AH, Gonzales P, Tran HV, Hinojosa JC, Kallas EG, Kelley CF, Lasso MH, Madruga JV, Middelkoop K, Phanuphak N, Santos B, Sued O, Valencia Huamani J, Overton ET, Swaminathan S, Del Rio C, Gulick RM, Richardson P, Sullivan P, Piwowar-Manning E, Marzinke M, Hendrix C, Li M, Wang Z, Marrazzo J, Daar E, Asmelash A, Brown TT, Anderson P, Eshleman SH, Bryan M, Blanchette C, Lucas J, Psaros C, Safren S, Sugarman J, Scott H, Eron JJ, Fields SD, Sista ND, Gomez-Feliciano K, Jennings A, Kofron RM, Holtz TH, Shin K, Rooney JF, Smith KY, Spreen W, Margolis D, Rinehart A, Adeyeye A, Cohen MS, McCauley M, Grinsztejn B; HPTN 083 Study Team. Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women. *N Engl J Med*. 2021 Aug 12;385(7):595-608. doi: 10.1056/NEJMoa2101016. PMID: 34379922; PMCID: PMC8448593.

Funding: This work was sponsored by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), and jointly funded by NIAID and ViiV Healthcare.

E-poster Contact: gbeatriz@ini.fiocruz.br

Presented at AIDS 2022 – The 24th International AIDS Conference

Regardless of study arm, at baseline, TGW enrolled in the study experienced an increased frequency of sexual (56.7% vs. 45.4%), physical (30.2% vs. 19.2%), and emotional (47.4% vs. 36.4%) interpersonal violence when compared to MSM. Further, when study participants were queried regarding their perceptions about HIV acquisition risk, self-perceived risk was lower for TGW as compared to MSM (44.4% vs. 32.5%).

TABLE 3. History of interpersonal violence and HIV risk perception in HPTN 083 study participants at baseline.

	Overall (n=4566)		TGW (n=570)		MSM (n=3996)	
	n	%	n	%	n	%
Interpersonal Violence						
Emotional Abuse	1724	37.8%	270	47.4%	1454	36.4%
Physical Abuse	939	20.6%	172	30.2%	767	19.2%
Sexual Abuse	2137	46.8%	323	56.7%	1814	45.4%
Low HIV risk perception ¹	1551	34.0%	253	44.4%	1298	32.5%

¹Related to the phrase "I am worried about getting infected with HIV," the options "strongly disagree," "disagree," "neither agree nor disagree," and "don't know" were classified as "low HIV risk perception".

CAB-LA was well tolerated in TGW; the frequency of grade 2+ AEs did not meaningfully differ between TGW receiving CAB-LA or TDF/FTC (92.5% vs. 88.8%). HIV incidence among TGW during the blinded phase of the trial was 1.80% (TDF/FTC) and 0.54% (CAB-LA) (hazard ratio: 0.343, 95% CI 0.08-1.56). Incidence of STIs among TGW were comparable between study arms.

TABLE 4. AE frequency and HIV and curable STI incidence among TGW during the blinded phase of HPTN 083, stratified by study arm.

	Overall (n=570)		TDF/FTC (n=304)		CAB-LA (n=266)	
	n	%	n	%	n	%
HIV incidence rate	9	1.19%	7	1.80%	2	0.54%
Syphilis incidence rate		16.3%		18.6%		13.8%
Gonorrhea (rectal) incidence rate		11.7%		11.8%		11.5%
Chlamydia (rectal) incidence rate		20.6%		22.6%		18.6%
Participants who received at least one injection	516	90.5%	266	87.5%	250	94.0%
Participants who reported any injection site reaction (ISR)	294	57.0%	77	28.9%	217	86.8%
Participants with Grade 2+ AEs	516	90.5%	270	88.8%	246	92.5%
Participants with Grade 3+ AEs	142	24.9%	76	25.0%	66	24.8%

CAB PK was compared in a subset of TGW in the presence or absence of GAHT; in this analysis, 30 participants accessed GAHT, while 23 participants were not using GAHT. Study participants in this analysis received all CAB-LA injections on-time through week 53. CAB drug concentrations were comparable between the two groups, suggesting the lack of a GAHT effect on CAB PK.




Figure 1. Concentration-time profiles of CAB in TGW in the absence (solid blue line) or presence (dotted red line) of GAHT.

Conclusions

- CAB-LA is a safe and effective HIV prevention strategy for TGW.
- Efficacy: During a median follow-up of 1.4 years, CAB-LA was superior to TDF/FTC in preventing incident HIV infection, and provided high levels of protection in TGW.
- Safety: The occurrence of grade 2+ AEs did not differ between study arms for TGW.
- Initial findings suggest GAHT does not impact CAB concentrations.